After the biomedical engineering degree, I studied as a Ph.D. student at Semmelweis University in Hungary, and I earned my doctoral degree in Pathology. One of my research areas was the study and development of new biomarkers for use on cervical liquid-based samples and on histological slides. In my doctoral dissertation, I focused on the study of autophagy and microRNA expression in chronic and neoplastic liver diseases in vivo and in vitro. Currently, at Karolinksa Universitet, I am working on a study in which the proposal aims at developing novel treatment regimens for highly resistant liver and pancreas cancer and in which the strategy is to create benefits out of the toxicity effects of Selenium compounds. The main focus of my work in the group of Mikael Björnstedt is concerned with the study of the molecular mechanisms underlying the cytotoxic effects of selenium-based treatment regimens. In addition, I analyze such microRNAs to combine with Selenium-based treatments to achieve a high accuracy in targeting pancreatic tumors, while minimizing the effect on normal cells. I hope that we can extend the group's ex vivo slice culture model to another cancer type such as Hepatocellular carcinoma or Cholangiocarcinoma
After the biomedical engineering degree, I studied as a Ph.D. student at Semmelweis University in Hungary, and I earned my doctoral degree in Pathology. One of my research areas was the study and development of new biomarkers for use on cervical liquid-based samples and on histological slides. In my doctoral dissertation, I focused on the study of autophagy and microRNA expression in chronic and neoplastic liver diseases in vivo and in vitro. Currently, at Karolinksa Universitet, I am working on a study in which the proposal aims at developing novel treatment regimens for highly resistant liver and pancreas cancer and in which the strategy is to create benefits out of the toxicity effects of Selenium compounds. The main focus of my work in the group of Mikael Björnstedt is concerned with the study of the molecular mechanisms underlying the cytotoxic effects of selenium-based treatment regimens. In addition, I analyze such microRNAs to combine with Selenium-based treatments to achieve a high accuracy in targeting pancreatic tumors, while minimizing the effect on normal cells. I hope that we can extend the group's ex vivo slice culture model to another cancer type such as Hepatocellular carcinoma or Cholangiocarcinoma